Recent breakthroughs in molecular biology emphasize the KIF15 therapeutic potential in modern medicine. KIF15 belongs to the kinesin-12 family of motor proteins. Primarily, it maintains the bipolar geometry of the mitotic spindle during cell division. Furthermore, researchers have identified KIF15 as a key factor in several human malignancies. Beyond cancer, genetic studies link KIF15 variants to chronic lung conditions like idiopathic pulmonary fibrosis.

Exploring KIF15 Therapeutic Potential in Cancer Mechanisms

Mechanistically, KIF15 drives several oncogenic processes across various solid tumors. It activates critical signaling pathways such as MEK-ERK and PI3K-AKT. Additionally, it helps cancer cells bypass resistance to Eg5 inhibitors. This adaptability makes it a dangerous driver of tumor progression. However, this same mechanism highlights the KIF15 therapeutic potential for combination therapies. For instance, using KIF15 inhibitors alongside standard treatments could improve patient outcomes.

In the context of respiratory health, KIF15 variants play a distinct role. Both rare and common genetic mutations can decrease protein expression in the lungs. Consequently, this reduction impairs the regenerative capacity of the lung epithelium. This process represents a non-telomerase pathway for pulmonary fibrosis development. Therefore, monitoring KIF15 levels could serve as a valuable diagnostic tool in the future.

Frequently Asked Questions

What is the role of KIF15 in cancer?

KIF15 maintains the mitotic spindle and promotes tumor growth through signaling pathways like MEK-ERK. Moreover, it helps cells overcome drug resistance.

Is KIF15 a potential drug target?

Yes, preclinical studies show that inhibiting KIF15 can restrict tumor progression. Researchers are currently exploring it as a candidate for combination anticancer strategies.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Xiang S et al. KIF15 (Kinesin-12): molecular biology, physiological functions, and roles in disease. J Cancer Res Clin Oncol. 2026 May 10. doi: 10.1007/s00432-026-06501-0. PMID: 42107035.

Zhang D et al. Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 Jul 1;206(1):56-69. doi: 10.1164/rccm.202110-2439OC.

Wang J et al. Kinesin 12 (KIF15) contributes to the development and tumorigenicity of prostate cancer. Biochem Biophys Res Commun. 2021 Oct 22;576:7-14. doi: 10.1016/j.bbrc.2021.08.072.